Given that GLS2 appears to play a larger role than GLS1 in glutamine consumption in HCC cell lines, we investigated whether GLS2 inhibition could have greater clinical efficacy in blunting HCC development. This evidence concerns the gene GLS and hepatocellular carcinoma.